Companies › Voronoi
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Other; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VRN101099 HER2 inhibitor | – | Phase 1 | Healthy Adult; HER2-positive Solid Tumors | Jul 2027 |
| VRN110755 Selective oral EGFR inhibitor targeting activating EGFR mutations and resistance mutations | EGFR | Phase 1 | EGFR-Mutant Non-Small Cell Lung Cancer | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07550946 | VRN101099 | Phase 1 | Healthy Adult | Other | Sep 2026 |
| NCT06806982 | VRN101099 | Phase 1 | HER2-positive Solid Tumors | Oncology | Jul 2027 |
| NCT07699328 | VRN110755 | Phase 1 | EGFR-Mutant Non-Small Cell Lung Cancer | Oncology | Jan 2029 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.